ArticleScientific reports2022
Chronic pancreatitis and cancer risk in a matched cohort study using national claims data in South Korea.
Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 24 citations in OpenAlex.
- Alcohol consumption and the risks of morbidity and mortality across 39 diseases and conditions: A population-based cohort study in Korea.Addiction (Abingdon, England) · 2026Article
- Development of a predictive model for pancreatic cancer integrating serum metabolomics and polygenic risk score.Frontiers in endocrinology · 2026Article
- All-cause and cause-specific mortality in chronic pancreatitis: A systematic review.Therapeutic advances in gastroenterology · 2026Review
- Association of Physical Activity with Dementia Risk in Cancer Survivors: A Korean Nationwide Cohort Study.Cancer research and treatment · 2026Article
- Mortality and cancer risk in patients with chronic pancreatitis in japan: insights into the importance of surveillance for pancreatic cancer.Journal of gastroenterology · 2026Article
- Methanol Extract fromAntioxidants (Basel, Switzerland) · 2025Article
- Tropisetron Suppresses Chronic Pancreatitis and Pancreatic Cancer by Blocking Interleukin 33 Expression.Cancers · 2025Article
- Review
- Chronic pancreatitis as a driving factor for pancreatic cancer: An epidemiological understanding.World journal of clinical oncology · 2024Article
- Incidence and risk of pancreatic cancer in patients with acute or chronic pancreatitis: a population-based cohort study.Scientific reports · 2023Article
- Catechin hydrate ameliorates cerulein‑induced chronic pancreatitis via the inactivation of TGF‑β/Smad2 signaling.Molecular medicine reports · 2023Article
- 5-FU-miR-15a Inhibits Activation of Pancreatic Stellate Cells by Reducing YAP1 and BCL-2 Levels In Vitro.International journal of molecular sciences · 2023Article
- Clinical and Biological Data in Patients with Pancreatic Cancer vs. Chronic Pancreatitis-A Single Center Comparative Analysis.Diagnostics (Basel, Switzerland) · 2023Article
- Incidence and risk of pancreatic cancer in patients with chronic pancreatitis: defining the optimal subgroup for surveillance.Scientific reports · 2023Article
- Impact of statin treatment on cardiovascular events in patients with retinal vein occlusion: a nested case-control study in Korea.Epidemiology and health · 2023Article
- A multifactorial analysis of FAP to regulate gastrointestinal cancers progression.Frontiers in immunology · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to examine the association between chronic pancreatitis (CP) and cancer incidence and mortality among the Korean population. Based on a cancer-free cohort of 8,317,616 individuals between 2002 and 2010, a matched cohort study was conducted, including 10,899 patients with CP, matched for sex and age with 32,697 individuals without CP. The case and control groups were followed up until the date of onset of cancer or death or the end of follow-up date (December 31, 2018). Cox proportional hazards regression was performed to assess the risk of cancer incidence and mortality. Compared to the control group, patients with CP had a higher risk of all cancers with a hazard ratio (HR) of 1.2 [95% confidence interval (CI) 1.1-1.3]. CP was associated with an increased risk of esophageal cancer (HR 3.9, 95% CI 1.8-8.5) and pancreatic cancer (HR 3.9, 95% CI 2.7-5.5) and a decreased risk of colorectal cancer (HR 0.7, 95% CI 0.5-0.9). Regarding cancer mortality, patients with CP had a 1.2-fold risk of all cancer mortality (95% CI 1.1-1.4), compared with the control group. Patients with CP had a higher risk of death from esophageal cancer (HR 3.5, 95% CI 1.5-8.0) and pancreatic cancer (HR 3.3, 95% CI 2.3-4.7) but had a lower risk of death due to stomach cancer (HR 0.4, 95% CI 0.2-0.8). Patients with CP had a higher risk for both incidence and mortality of all cancer types, especially pancreatic and esophageal cancers, compared with the sex- and age-matched control group.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.